Upcoming Data Release#
Entrada Therapeutics, Inc. (NASDAQ:TRDA) is set to announce the topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 clinical study on Thursday. This study focuses on ENTR-601-44, a potential treatment for genetic diseases.
Stock Performance#
In the past week, Entrada's stock has seen a significant increase of 24%, currently trading at $16.03. This price is just 1% below its 52-week high of $16.19, indicating strong investor interest leading up to the trial data release.
Study Details#
The ELEVATE-44-201 study is a double-blind, placebo-controlled trial, meaning that neither the participants nor the researchers know who is receiving the treatment or a placebo. This design helps ensure that the results are unbiased. The study involves multiple ascending doses, which means that different groups of participants will receive varying doses to assess safety and effectiveness.
Investor Engagement#
To discuss the clinical results, Entrada Therapeutics will host a webcast and conference call at 8:30 a.m. ET on Thursday. Investors can access this event through the investor relations section of the company’s website, and it will be available for replay for 90 days after the call.
Entrada Therapeutics is focused on developing genetic medicines aimed at treating neuromuscular and inherited retinal diseases, with its lead programs targeting Duchenne muscular dystrophy in specific patient groups.